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We describe a case report of fulminant Guillain–Barré syndrome (GBS) mimicking brain 
death. A previously healthy 60-year-old male was admitted to the neurointensive care 
unit after developing rapidly progressive weakness and respiratory failure. On presenta-
tion, the patient was found to have absent brainstem and spinal cord reflexes resembling 
that of brain death. Acute motor axonal neuropathy, a subtype of GBS, was diagnosed 
by cerebrospinal fluid and nerve conduction velocity testing. An electroencephalogram 
showed that the patient had normal, appropriately reactive brain function. Transcranial 
Doppler (TCD) ultrasound showed appropriate blood flow to the brain. GBS rarely pres-
ents with weakness so severe as to mimic brain death. This article provides a review of 
similar literature. This case demonstrates the importance of performing a proper brain 
death examination, which includes evaluation for irreversible cerebral injury, exclusion of 
any confounding conditions, and performance of tests such as electroencephalography 
and TCDs when uncertainty exists about the reliability of the clinical exam.
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BaCKGRoUND
Guillain–Barré syndrome (GBS) is a term used to describe a group of acute, immune-mediated 
polyneuropathies that are clinically characterized by rapidly progressive, symmetrical, ascend-
ing weakness, and hyporeflexia. The two most common subtypes of GBS are acute inflammatory 
demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), with AIDP 
representing 60–80% of cases (1). The incidence of AMAN is less clear but seems to vary between 
geographical locations. Its frequency is estimated at 6–7% in the UK and Spain, and 30–65% in Asia, 
Central America, and South America. It is postulated that geographical variation is due to differences 
in infectious exposures and genetic susceptibilities. Overall, AMAN is likely underdiagnosed or 
incorrectly diagnosed as AIDP (1–9).
The degree of muscle weakness in GBS is variable but can be severe with 25% of patients requiring 
mechanical ventilation from respiratory failure (1, 10–15). In this case report, we describe a patient 
with fulminant AMAN whose clinical presentation mimicked brain death beginning 7 days after 
the onset of symptoms, and lasting for 7 days before return of central nervous system function on 
clinical examination.
FIGURe 1 | transcranial Doppler study shows preserved cerebral blood flow in the middle, anterior, and posterior cerebral arteries.
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INtRoDUCtIoN
A 60-year-old male with diabetes mellitus, hypertension, and 
chronic obstructive pulmonary disease presented to a local 
community hospital with worsening shortness of breath. Two 
days prior, he was discharged from a 2-week hospital stay for 
community-acquired pneumonia complicated by empyema 
requiring chest tube placement. There was no history of recent 
vaccination, diarrheal illness, or recent travel. He was endorsing 
subjective bilateral lower extremity weakness, back pain, and 
difficulty urinating on the days leading up to admission.
eXaM, DIaGNosIs, aND tReatMeNt
The initial neurological exam on the day of admission to the com-
munity hospital was normal. Later that day, the patient developed 
ascending right-sided weakness and numbness involving his leg 
and arm with hyporeflexia noted in the right upper and lower 
extremities. On hospital day 2, the patient developed ascending 
left-sided leg and arm weakness and numbness. That day, he 
developed facial muscle and bulbar weakness that progressed to 
an inability to speak or eat. Cerebral spinal fluid (CSF) analysis 
within 48 h of initial presentation revealed an albuminocytologic 
dissociation, with 0 white blood cells present and a protein level of 
103. Laboratory work-up in serum and CSF showed no growth on 
bacterial cultures and a negative viral and fungal work-up. MRI 
of the brain, cervical, and lumbar spine was negative for acute 
changes. On hospital day 3, the patient was started on IVIg for 
treatment of suspected AIDP. Despite treatment, his condition 
continued to deteriorate with generalized weakness progress-
ing to respiratory failure requiring intubation. By hospital day 
5, cranial nerve function was clinically lost, characterized by 
absent pupillary responses, corneal responses, vestibulo-ocular 
reflexes, and gag and cough reflexes. Additionally, the patient had 
progressed to flaccid quadriplegia and was no longer triggering 
spontaneous breaths on mechanical ventilation. Based on his 
clinical exam, there was concern from his providing physician 
that the patient may have met criteria for brain death, and the 
family was told that his prognosis was extremely poor and most 
likely not compatible with life.
On hospital day 6, the patient was transferred to our neurosci-
ence intensive care unit at an academic tertiary care center. Our 
exam confirmed absence of cranial nerve function, absence of 
patient-triggered breaths on mechanical ventilation, complete 
flaccid tetraplegia with lack of response to noxious stimuli, and 
absence of all deep tendon reflexes. Although the clinical exam 
mimicked brain death, there was uncertainty about the reliability 
of the exam because of the lack of history or imaging supporting 
the presence of catastrophic brain injury. Because of this, a 24-h 
electroencephalogram (EEG) was completed, which confirmed 
the presence of cortical brain activity with preserved background 
rhythms and reactivity. Transcranial Doppler (TCD) ultrasound 
demonstrated preserved cerebral blood flow (Figure  1). While 
AIDP remained highest on the differential due to the patient’s 
pattern of ascending weakness and albuminocytologic dissocia-
tion in spinal fluid, other considerations included varicella virus 
(VZV) neuropathy, West Nile polio-like myelitis, vasculitic 
neuropathy, and heavy metal poisoning due to the patient’s prior 
history of working in a plastics factory. VZV PCR in the CSF was 
undetectable. Serum and CSF West Nile antibody were negative. 
Vasculitis work-up, including ANA, ANCA, and complement 
studies, was negative. Heavy metal screen was negative. A lum-
bar puncture was repeated on hospital day 7 with CSF showing 
persistent albuminocytologic dissociation (408 RBC; 0 WBC; 339 
protein; 121 glucose). Serum anti-GQ1B and anti-GM1 antibod-
ies were negative. A nerve conduction study was performed on 
hospital day 8, which is presented in Figure  2. Motor action 
potential responses in bilateral upper and lower extremities were 
completely absent, while the left sensory radial nerve showed a 
preserved signal with low amplitude and delayed peak latency, 
although a full sensory study was difficult to obtain in the ICU 
setting. The diagnosis based on nerve conduction velocity results 
was AMAN.
Prior to transfer to our hospital, the patient was treated with 
empiric IVIg for 3 days for a presumptive diagnosis of AIDP. 
Because of progression of symptoms despite treatment with 
FIGURe 2 | Nerve conduction results. Motor responses were absent in bilateral upper and lower extremities. Radial nerve sensory action potential was present 
but showed delayed latency and reduced amplitude.
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IVIg, on hospital day 7, he was switched to plasmapheresis for a 
7-day course. The patient began breathing above the set ventilator 
rate on hospital day 11. On hospital day 14, the patient regained 
trace, non-purposeful neck movements. On hospital day 19, 
he began to open and close his mouth spontaneously, and on 
hospital day 27, he began to follow commands with his mouth 
and tongue. The patient’s hospital course was complicated by 
intermittent tachycardia and labile blood pressures suggestive 
of autonomic instability. He eventually underwent percutane-
ous tracheostomy and gastrostomy tube placement. Thirty-two 
days after his initial admission, the patient was discharged to a 
long-term acute care facility able to move his head, mouth, and 
tongue to command; however, he remained areflexic and plegic 
in all four extremities and had complete ophthalmoplegia and 
non-reactive pupils. Six months after his initial admission, the 
patient remained in a long-term acute care facility with high 
ventilator requirements, although he regained proximal arm 
and leg strength. He was able to sit up in a chair and mouth 
words to communicate.
DIsCUssIoN
This case report describes a patient with fulminant AMAN with 
progressive loss of appendicular strength and deep tendon reflexes 
leading to areflexic quadriplegia, respiratory muscle weakness 
progressing to respiratory failure, and loss of brainstem reflexes. 
The providers at the community hospital mistakenly thought that 
the patient’s presentation was consistent with brain death based 
on (1) absence of spontaneous movements or posturing; (2) 
absent direct and consensual pupillary light reflexes; (3) absent 
corneal, oculocephalic, cough, and gag reflexes; and (4) absent 
oculovestibular reflexes. A formal apnea test likely would have 
had significant CO2 retention meeting diagnostic threshold due 
to absent respiratory muscle function requiring full ventilatory 
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support. According to the brain death criteria from the American 
Academy of Neurology (14), however, before diagnosing brain 
death, it is a requirement to evaluate for proximate and irrevers-
ible injury to the brain and to pursue testing with EEG and TCD 
ultrasound when uncertainty exists about the reliability of the 
physical exam or when the apnea test cannot be performed. Based 
on the lack of evidence for brain injury as well as EEG and TCD 
studies demonstrating preserved cerebral function, the criteria 
for brain death were not fulfilled. The diagnosis of AMAN was 
made by clinical history, albuminocytologic dissociation in CSF, 
and nerve conduction velocity testing.
The natural course of fulminant AMAN and other GBSs 
is largely unknown given there are only a few other reports of 
severe GBS mimicking brain death. Fulminant GBS has been 
reported in a wide distribution of ages and ethnicities (15–21). 
In our patient, total absence of motor, respiratory, and brainstem 
function occurred for a total of 7  days, similar to the cases 
described by Liik et al. and Friedman et al., although these cases 
were diagnosed as acute motor and sensory axonal neuropathy 
(AMSAN) (18, 21). In other cases presented in the literature, elec-
trophysiological studies were also paramount in establishing the 
diagnosis (15–21). Acute axonal neuropathies, such as AMAN 
and AMSAN, have been reported to have a rapid progression 
and a prolonged recovery time compared to acute demyelinating 
neuropathies (4, 21, 22). The clinical differences may be related 
to underlying differences in mechanism, as the axolemma and 
nodes of Ranvier are targeted in AMAN compared to Schwann 
cells being targeted in AIDP. AMAN is more likely to have positive 
anti-GM1 and anti-GD1 antibodies compared to AIDP and more 
likely to be associated with a preceding Campylobacter infection, 
making molecular mimicry a potential etiology (4, 23). While our 
patient’s rapid and severe presentation is similar to other reports 
of fulminant acute axonal neuropathy, this is not the classic pres-
entation for AMAN. AMAN typically does not involve cranial 
nerves and is not typically associated with autonomic lability 
(4). It remains unknown which factors predispose patients to 
having more fulminant courses of GBS. Our patient did have the 
commonly cited complications of GBS, which include autonomic 
dysfunction presenting as persistent tachycardia, hypertension, 
gastrointestinal dysfunction, and bladder dysfunction (1, 24). 
Respiratory insufficiency, pulmonary infection, autonomic 
dysfunction, and cardiac arrest are the most common causes of 
death in GBS (1, 25–27). In terms of the treatment of GBS, the 
only proven effective therapies are IVIg and plasma exchange 
(1,  3, 28). There are currently no controlled studies suggesting 
that either IVIg or plasma exchange are superior to one another 
in treating GBS (1). Furthermore, studies have failed to show that 
combination therapy with plasma exchange followed by IVIG is 
more effective than either therapy alone (1, 11, 27). The decision 
in our patient to start plasmapheresis after 3 days of IVIg was due 
to clinical deterioration despite IVIg treatment. Motor recovery 
from severe forms of GBS can be expected to be prolonged, with 
progressive recovery over a period of months to 3  years being 
reported (15–19). In contrast, cognitive function and memory 
may be relatively preserved although some difficulty with recall 
may be expected (16).
CoNCLUDING ReMaRKs
This case highlights the importance of recognizing fulminant 
AMAN and other GBSs as a mimicker of clinical brain death 
and a cause of a “locked-in” state, especially in the absence of 
catastrophic brain injury. Awareness of the potential clinical 
manifestations and long-term prognosis of fulminant GBS is 
crucial for both acute management of these patients and for 
education and counseling provided to family members and other 
health-care providers.
etHICs stateMeNt
The study is a description of a clinical case with a literature review. 
There were no experimental methods used that would necessitate 
the approval of an ethics committee. Consent from the patient’s 
daughter was obtained to allow for publication of this case report. 
The patient’s daughter was assured that the report would remain 
anonymous and that no personal identifiers would be used. The 
patient was not able to give consent due to his clinical condition.
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